Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathieu Simonin

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Bulletin Du Cancer|July 21, 2022
[Practical management during maintenance therapy of pediatric acute lymphoblastic leukemia: Recommendations of the French Society for Childhood and Adolescent Cancer and Leukemia (SFCE)]Paul Saultier, Mathieu Simonin, Tiphaine Adam de Beaumais, et al.
Blood|June 14, 2021
PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALLGuillaume P Andrieu, Milena Kohn, Mathieu Simonin, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 14, 2023
Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphomaBéranger Lueza, Anne Aupérin, Charlotte Rigaud, et al.
Blood|November 5, 2020
IKZF1 alterations predict poor prognosis in adult and pediatric T-ALLMathieu Simonin, Ludovic Lhermitte, Marie-Emilie Dourthe, et al.
Haematologica|March 3, 2022
Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective studyMarie Emilie Dourthe, Aurélie Phulpin, Anne Auperin, et al.
Blood Advances|July 5, 2019
Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemiaMarion Alcantara, Mathieu Simonin, Ludovic Lhermitte, et al.
Blood|August 26, 2025
LEF1 Intragenic Deletion Induces a Dominant-Negative isoform and unveils a Wnt/β3-Catenin Vulnerability in T-ALLManon Delafoy, Mickaël Frédéric Bonnet, Etienne Lengliné, et al.
Blood|January 27, 2026
Homeodomain-driven oncogenic diversion to a TCRγδ phenotype in T-cell Acute Lymphoblastic LeukemiaAntoine Pinton, Lucien Courtois, Manon Delafoy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and VenetoclaxAntoine Pinton, Lucien Courtois, Charlotte Doublet, et al.
Blood|April 6, 2023
IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibitionLucien Courtois, Aurélie Cabannes-Hamy, Rathana Kim, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Bulletin Du Cancer|July 21, 2022
[Practical management during maintenance therapy of pediatric acute lymphoblastic leukemia: Recommendations of the French Society for Childhood and Adolescent Cancer and Leukemia (SFCE)]Paul Saultier, Mathieu Simonin, Tiphaine Adam de Beaumais, et al.
Blood|June 14, 2021
PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALLGuillaume P Andrieu, Milena Kohn, Mathieu Simonin, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 14, 2023
Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphomaBéranger Lueza, Anne Aupérin, Charlotte Rigaud, et al.
Blood|November 5, 2020
IKZF1 alterations predict poor prognosis in adult and pediatric T-ALLMathieu Simonin, Ludovic Lhermitte, Marie-Emilie Dourthe, et al.
Haematologica|March 3, 2022
Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective studyMarie Emilie Dourthe, Aurélie Phulpin, Anne Auperin, et al.
Blood Advances|July 5, 2019
Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemiaMarion Alcantara, Mathieu Simonin, Ludovic Lhermitte, et al.
Blood|August 26, 2025
LEF1 Intragenic Deletion Induces a Dominant-Negative isoform and unveils a Wnt/β3-Catenin Vulnerability in T-ALLManon Delafoy, Mickaël Frédéric Bonnet, Etienne Lengliné, et al.
Blood|January 27, 2026
Homeodomain-driven oncogenic diversion to a TCRγδ phenotype in T-cell Acute Lymphoblastic LeukemiaAntoine Pinton, Lucien Courtois, Manon Delafoy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and VenetoclaxAntoine Pinton, Lucien Courtois, Charlotte Doublet, et al.
Blood|April 6, 2023
IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibitionLucien Courtois, Aurélie Cabannes-Hamy, Rathana Kim, et al.
Pageof 5